SEELOS THERAPEUTICS INC (SEEL)
US81577F3073 - Common Stock
SEEL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. SEEL may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, SEEL is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
SEEL had negative earnings in the past year.
In the past year SEEL has reported a negative cash flow from operations.
In the past 5 years SEEL always reported negative net income.
SEEL had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 171.82%, SEEL belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 171.82% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-367.19%
ROA(5y)-334.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of SEEL (203.13%) is better than 99.48% of its industry peers.
The Operating Margin and Gross Margin are not available for SEEL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 203.13% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for SEEL has been increased compared to 1 year ago.
The number of shares outstanding for SEEL has been increased compared to 5 years ago.
Compared to 1 year ago, SEEL has a worse debt to assets ratio.
2.2 Solvency
SEEL has an Altman-Z score of -203.76. This is a bad value and indicates that SEEL is not financially healthy and even has some risk of bankruptcy.
SEEL has a Altman-Z score of -203.76. This is amonst the worse of the industry: SEEL underperforms 97.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -203.76 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
SEEL has a Current Ratio of 0.08. This is a bad value and indicates that SEEL is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.08, SEEL is doing worse than 99.48% of the companies in the same industry.
A Quick Ratio of 0.08 indicates that SEEL may have some problems paying its short term obligations.
The Quick ratio of SEEL (0.08) is worse than 98.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.08 | ||
| Quick Ratio | 0.08 |
3. Growth
3.1 Past
SEEL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -318.47%.
The Revenue has grown by 76.05% in the past year. This is a very strong growth!
EPS 1Y (TTM)-318.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.27%
Revenue 1Y (TTM)76.05%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.9%
3.2 Future
SEEL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.17% yearly.
Based on estimates for the next years, SEEL will show a very strong growth in Revenue. The Revenue will grow by 195.91% on average per year.
EPS Next Y97.05%
EPS Next 2Y41.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-81.25%
Revenue Next 2Y321.31%
Revenue Next 3Y402.41%
Revenue Next 5Y195.91%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
SEEL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SEEL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SEEL's earnings are expected to grow with 41.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.17%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for SEEL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SEELOS THERAPEUTICS INC
NASDAQ:SEEL (10/15/2024, 8:00:02 PM)
After market: 1.45 +0.17 (+13.28%)1.28
-1.17 (-47.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners21.58%
Inst Owner Change-55.53%
Ins Owners73.41%
Ins Owner Change0%
Market Cap563.20K
Analysts85.71
Price Target122.4 (9462.5%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)56.05%
Min Revenue beat(2)22.88%
Max Revenue beat(2)89.22%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.28 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-45.32
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-30.17
FCFYN/A
OCF(TTM)-30.17
OCFYN/A
SpS4.58
BVpS-63.94
TBVpS-63.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 171.82% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 203.13% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-367.19%
ROA(5y)-334.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.85
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.08 | ||
| Quick Ratio | 0.08 | ||
| Altman-Z | -203.76 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-318.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.27%
EPS Next Y97.05%
EPS Next 2Y41.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)76.05%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.9%
Revenue Next Year-81.25%
Revenue Next 2Y321.31%
Revenue Next 3Y402.41%
Revenue Next 5Y195.91%
EBIT growth 1Y46.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y79.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y79.98%
OCF growth 3YN/A
OCF growth 5YN/A